VANCOUVER, BC – Aequus Pharmaceuticals Inc. (TSX-V: AQS,OTCQB: AQSZF)(“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce a… Read More
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson’s disease ABL301 uses… Read More
Opportunity to accelerate your company with Takeda Canada through dedicated funding for a proof-of-concept project. The Takeda Canada Innovation Challenge opens on January 10, 2022 and will accept applications until February 6, 2022…. Read More
Acquisition Adds Adaptate’s Novel Antibody-based γδ T-cell Engager Platform to Takeda’s Immuno-oncology Portfolio Built Around the Innate Immune System Successful Multi-year R&D Partnership Results in Takeda’s Third Oncology “Build-to-Buy” Acquisition… Read More
VANCOUVER, BC – Eyam Vaccines and Immunotherapeutics is pleased to publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the Board of Directors, and the appointment… Read More
